Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors
Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer,…
Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer,…
Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic…
Cellectis, the €1bn CAR-T company, just announced it reached a significant milestone in its collaboration…
It's becoming a habit for us to talk about CAR-T therapies. It's basically the next…
[UPDATE 19/06/2015]: Yesterday, Celyad launched its IPO on NASDAQ and the closing is expected to occur…
[Update] Bloomberg announced that they make wrong conclusions from their discussion with AstraZeneca's CEO Pascal…
Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer…
Oxford-based Adaptimmune has launched its IPO on NASDAQ, where the immunotherapist plans to raise about €156.7M. The company…
Juno Therapeutics has purchased Stage Cell Therapeutics, a privately held biotechnology company, based in Munich…
Just a week after announcing its intention to launch an IPO in the United States,…
A promising biotechnological approach or an innovative way of avoiding regulation? Large companies spend an…
Merck Sereno, the biopharmaceutical business of Merck, and the synthetic biology leader Intrexon announced yesterday an exclusive strategic…